Hepatitis C Hepatitis C More than 95% of people with chronic infection can be cured when treated with medications; this could be expensive, but by 2022 prices had dropped dramatically.  The combination of sofosbuvir, velpatasvir, and voxilaprevir may be used in those who have previously been treated with sofosbuvir or other drugs that inhibit NS5A and were not cured. Prior to 2011, treatments consisted of a combination of pegylated interferon alpha and ribavirin for a period of 24 or 48 weeks, depending on HCV genotype.  This treatment produces cure rates of between 70 and 80% for genotype 2 and 3, respectively, and 45 to 70% for genotypes 1 and 4.  Adverse effects with these treatments were common, with 50 to 60% of those being treated experiencing flu-like symptoms and nearly a third experiencing depression or other emotional issues.  Treatment during the first six months of infection  is more effective than when hepatitis C has entered the chronic stage.  In those with chronic hepatitis B, treatment for hepatitis C results in reactivation of hepatitis B about 25% of the time Hepatitis C Hepatitis C